Research Overview
Transfecting RNAi into Target Cells Proves to be a Significant Challenge
Delivering or transfecting ribonucleic acid interference (RNAi) into
mammalian cells is one of the biggest challenges facing researchers. In
addition, a tedious optimization process is a prerequisite for the transfection
of standard cell lines with commonly used lipofection reagents. Successful
delivery of RNAi depends on a few key factors such as the target cell line, RNAi
concentration, the ratio of RNAi to the transfection reagent, cell confluence
during transfection, and incubation time. Another challenge lies in improving
the target specificity of RNAi. In this regard, a well designed RNAi has greater
chances of success in targeting the messenger RNA (mRNA) of interest and
minimizing off-target effects. In order to test and compare RNAi sequences,
researchers need to monitor and optimize RNAi purity and integrity, its uptake,
and cell viability.
This Frost & Sullivan research analyzes emerging technologies and
applications in RNAi design and delivery. Technological trends, drivers,
challenges, and recent developments assist in creating effective marketing and
production strategies. Participants can identify potential collaborators, stay
ahead of the competition, and keep abreast of critical developments in their
industry.
Failure of Related Researches and Technologies Sparks Interest in RNAi
Projects
After disappointing results from genomic projects involving antisense
technologies and ribozyme projects for gene therapy, researchers are looking at
RNAi for a more positive feedback. Since its discovery in 1998, the number of
published research papers pertaining to RNAi has skyrocketed from 15 to nearly
1,000 in 2003. "The potential this technology holds is amazing, as it
provides a new approach to drug discovery, validation, and delivery, amongst
other advantages," says the analyst. Given its recent successes in
attacking viruses such as HIV, and hepatitis B and C, RNAi holds immense
potential for quicker drug delivery. RNAis reach is expected to expand in the
future, as it attains the capabilities for treating renal and metabolic
disorders, and diseases such as cancers and those pertaining to the central
nervous system.
RNAi Moves from the Realms of High Throughput Screening to Therapeutics
While RNAi expertise, at present, lies primarily in high-throughput screening
(HTS), the technology is set to begin clinical trials and RNAi-based drugs might
be a reality by 2010. RNAi therapies that are likely to reach humans first are
those targeting macular degeneration, a leading cause of blindness. "Caused
by over expression of vascular endothelial growth factor (VEGF) in cells in the
back of the eye, the disease has several attributes that make it an ideal RNAi
showcase," explains the analyst.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new
theories tested in hundreds of companies across many industries, Frost &
Sullivan has evolved its Growth Partnership Services (GPS) program that provides
established and emerging firms with powerful growth visions. Moving beyond token
mission statements, GPS provides an actionable vision to growth consulting
partners by illustrating how key intelligence and strategic research based on
defined goals can guide day-to-day behavior and overall company direction. The
foundation of Frost & Sullivans GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related
businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common
mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximize the potential for growth within a firms internal and external
environment, Frost & Sullivan consultants can facilitate the creation of
strategic programs that deliver improved market success. Frost &
Sullivans strengths lie in combining strategic understanding with market
expertise and applying these with absolute commitment to its clients growth.
1 EXECUTIVE SUMMARY
- Introduction
- RNAi Technology in Brief
- Overview of the RNAi Sector
- Scope and Methodology
- Research Scope
- Research Methodology
2 RESEARCH DEVELOPMENTS IN RNAI DESIGN
- Research in the Private Sector
- The Silencer Effect (USA)
- DNA-Based siRNA Constructs (USA)
- Novel RNAi Expression Cassettes (USA)
- Increase RNAi Stability by Chemical Modifications (Belgium)
- Research in the Public Sector
- Inhibit More Genes Simultaneously (USA)
- Take the siDirect Approach (Japan)
- UMMS Provides Exclusive RNAi Technologies (USA)
3 RESEARCH DEVELOPMENTS IN RNAI DELIVERY
- Research in the Private Sector
- Explore Electroporation for Efficient RNAi Delivery (Germany)
- Mouse Musings?Development of RNAi Knockdown in Mice (Germany)
- Novel Lipid and Polymer-Based Transfection Reagents (USA)
- Adenoviral siRNA Library (Belgium)
- Electroporation for Vascular Gene Therapy (USA)
- Research in the Public Sector
- Research Liposome Technology as Delivery Vehicles (Netherlands)
- Nonviral Vectors and Formulations (France)
4 RESEARCH DEVELOPMENTS IN RNAI APPLICATIONS
- Research in the Private Sector
- RNAi Candidate for Liver Cancer (Germany)
- Treat AMD and DR with RNAi (USA)
- C. elegans as an Animal Model for Human Diseases (Belgium)
- RNAi for Nonhuman Therapeutics (USA)
- Novel Nucleotide Chemistry enhances siRNA Therapeutics (Denmark)
- Genome Wide siRNA Screening (Germany)
- siRNA-Based SARS Virus Inhibitors (USA)
- siRNA Agent Slows Macular Degeneration In Animals (USA)
- Research in the Public Sector
- TargeTran siRNA Nanoparticle Technology (USA)
- RNAi Gene Therapy for HIV Infection (USA)
5 RNAI SECTOR--TECHNOLOGY ASSESSMENT
- Sector Trend Analysis
- Technology Trends
- Corporate Collaborations (Part I)
- Corporate Collaborations (Part II)
- RNAi Technology Drivers and Challenges
- Technology Drivers
- Technology Challenges
6 KEY CONTACTS AND NOTEWORTHY PATENTS
- Key Contacts
- Industry Contacts
- University Contacts
- Important Patents
- Patents Part I
- Patents Part II
7 FROST & SULLIVAN 2004 SCIENCE AND TECHNOLOGY AWARDS
- Excellence in Research
- Award Description
- Award Recipient
- Excellence in Technology
- Award Description
- Award Recipient
- Technology Innovation Award
- Award Description
- Award Recipient
8 RELEVANT DECISION SUPPORT DATABASE (DSD) TABLES
- Healthcare Expenditure
- Government Healthcare Expenditure (1999 to 2006)
- Private Healthcare Expenditure (1999 to 2006)
- Total Healthcare Expenditure (1999 to 2006)
- Percentage Healthcare Expenditure (1999 to 2006)
- Per Capita Healthcare Expenditure (1999 to 2006)
- Pharma R & D Expenditure
- Pharma R & D Expenditure (1999 to 2006)
- Percentage Pharma R&D Expenditure (1999 to 2006)
- Cancer Incidence and Mortality
- Breast Cancer Incidence (1999 to 2006)
- Breast Cancer Mortality (1999 to 2006)
- Liver Cancer Incidence (1999 to 2006)
- Liver Cancer Mortality (1999 to 2006)
- Cataract and Diabetes
- Cataract Blindness (1999 to 2006)
- Cataract Surgeries (1999 to 2006)
- Diabetes Incidence (1999 to 2006)
- Diabetes Prevalence (1999 to 2006)
バイオテクノロジー
その他のカテゴリ
FAQ